Core Viewpoint - Soleno Therapeutics, Inc. is actively engaged in the development of novel therapeutics for rare diseases, with a focus on its lead candidate DCCR for Prader-Willi syndrome, which is currently under FDA review [1][3]. Company Participation - Management of Soleno Therapeutics will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024, at 9:00 AM Eastern Time [1]. Product Development - The company’s lead candidate, DCCR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for Prader-Willi syndrome and has been granted Priority Review by the FDA [3]. Investor Engagement - A live audio webcast and replay of the fireside chat will be accessible in the Investors section on the company's website [2].
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference